Deciphering the role of QPCTL in glioma progression and cancer immunotherapy
暂无分享,去创建一个
Lei Wu | Yufeng Shi | Xi Chen | Fei Wang | Shibo Yu | Xi Chen | Hui Yang | Hui Yang | Yihong Sun | Yue-ting Liu | S. Lu | Kai-li Zhao
[1] Yufeng Shi,et al. Functions of glutaminyl cyclase and its isoform in diseases , 2023, Visualized Cancer Medicine.
[2] Taiwen Li,et al. TISCH2: expanded datasets and new tools for single-cell transcriptome analyses of the tumor microenvironment , 2022, Nucleic Acids Res..
[3] J. Barnholtz-Sloan,et al. CBTRUS Statistical Report: Pediatric Brain Tumor Foundation Childhood and Adolescent Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018. , 2022, Neuro-oncology.
[4] R. Burger,et al. Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab , 2022, Frontiers in Immunology.
[5] Y. Liu,et al. Intracavity generation of glioma stem cell–specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy , 2022, Science Translational Medicine.
[6] Wei Wu,et al. Co-delivery of phagocytosis checkpoint and STING agonist by a Trojan horse nanocapsule for orthotopic glioma immunotherapy , 2022, Theranostics.
[7] M. Schrappe,et al. Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL. , 2022, Blood.
[8] Aijun Wang,et al. Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion , 2022, Nature Communications.
[9] T. Schumacher,et al. QPCTL regulates macrophage and monocyte abundance and inflammatory signatures in the tumor microenvironment , 2022, Oncoimmunology.
[10] Qing Li,et al. Uncovering the Immune Cell Infiltration Landscape in Low-Grade Glioma for Aiding Immunotherapy , 2022, Journal of oncology.
[11] Betty Y. S. Kim,et al. Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target , 2022, Nature communications.
[12] Mariella G. Filbin,et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas , 2022, Nature.
[13] J. Wargo,et al. Mechanisms of immune activation and regulation: lessons from melanoma , 2022, Nature Reviews Cancer.
[14] S. Rutz,et al. Loss of the intracellular enzyme QPCTL limits chemokine function and reshapes myeloid infiltration to augment tumor immunity , 2022, Nature Immunology.
[15] J. Serody,et al. B Cell Function in the Tumor Microenvironment , 2022, Annual Review of Immunology.
[16] C. Brennan,et al. Quiescent human glioblastoma cancer stem cells drive tumor initiation, expansion, and recurrence following chemotherapy. , 2022, Developmental cell.
[17] R. Appay,et al. [The 2021 WHO classification of tumours of the central nervous system]. , 2021, Annales de pathologie.
[18] M. Hadamitzky,et al. Glioma: molecular signature and crossroads with tumor microenvironment , 2021, Cancer and Metastasis Reviews.
[19] J. Barnholtz-Sloan,et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018. , 2021, Neuro-oncology.
[20] Susan M. Chang,et al. Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. , 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] Guohua Yang,et al. Dissecting Prognosis Modules and Biomarkers in Glioblastoma Based on Weighted Gene Co-Expression Network Analysis , 2021, Cancer management and research.
[22] Changming Tan,et al. Research status and the prospect of POSTN in various tumors. , 2021, Neoplasma.
[23] L. Qu,et al. QPCT regulation by CTCF leads to sunitinib resistance in renal cell carcinoma by promoting angiogenesis , 2021, International journal of oncology.
[24] P. Scheltens,et al. Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD—VIVIAD , 2021, Alzheimer's Research & Therapy.
[25] Anxun Wang,et al. Arecoline induces epithelial‐mesenchymal transformation and promotes metastasis of oral cancer by SAA1 expression , 2021, Cancer science.
[26] Alyssa R. Richman,et al. Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis , 2021, Cell.
[27] N. Kanemitsu,et al. Chronic treatment with the (iso-)glutaminyl cyclase inhibitor PQ529 is a novel and effective approach for glomerulonephritis in chronic kidney disease , 2020, Naunyn-Schmiedeberg's Archives of Pharmacology.
[28] E. Kenigsberg,et al. Serum Amyloid A Proteins Induce Pathogenic Th17 Cells and Promote Inflammatory Disease , 2020, Cell.
[29] M. Lleonart,et al. Therapy-Induced Modulation of the Tumor Microenvironment: New Opportunities for Cancer Therapies , 2020, Frontiers in Oncology.
[30] J. Kros,et al. Periostin Is Expressed by Pericytes and Is Crucial for Angiogenesis in Glioma. , 2020, Journal of neuropathology and experimental neurology.
[31] Blaine R. Roberts,et al. Increased glutaminyl cyclase activity in brains of Alzheimer’s disease individuals , 2020, Journal of neurochemistry.
[32] Jie Dong,et al. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma , 2020, Frontiers in Immunology.
[33] T. Takayama,et al. Cancer‐associated adipocytes promote pancreatic cancer progression through SAA1 expression , 2020, Cancer science.
[34] X. Liu,et al. Large-scale public data reuse to model immunotherapy response and resistance , 2020, Genome Medicine.
[35] Z. Wang,et al. Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data for Chinese Glioma Patients , 2020, bioRxiv.
[36] A. Faried,et al. Identification of Periostin as a Potential Biomarker in Gliomas by Database Mining. , 2019, World neurosurgery.
[37] I. Weissman,et al. Irradiation or temozolomide chemotherapy enhances anti-CD47 treatment of glioblastoma , 2019, Innate immunity.
[38] H. Tian,et al. Identification of Glutaminyl Cyclase isoenzyme isoQC as a regulator of SIRPα-CD47 axis , 2019, Cell Research.
[39] T. Schumacher,et al. Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and target for cancer immunotherapy , 2019, Nature Medicine.
[40] I. Weissman,et al. Microglia are effector cells of CD47-SIRPα antiphagocytic axis disruption against glioblastoma , 2019, Proceedings of the National Academy of Sciences.
[41] X. Liu,et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response , 2018, Nature Medicine.
[42] Edward F. Chang,et al. Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. , 2017, Cancer cell.
[43] Theresa A. Storm,et al. Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors , 2017, Science Translational Medicine.
[44] Matthew E. Ritchie,et al. limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.
[45] G. Getz,et al. Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.
[46] Guangchuang Yu,et al. clusterProfiler: an R package for comparing biological themes among gene clusters. , 2012, Omics : a journal of integrative biology.
[47] P. Quax,et al. The isoenzyme of glutaminyl cyclase is an important regulator of monocyte infiltration under inflammatory conditions , 2011, EMBO molecular medicine.
[48] A. Kehlen,et al. Isolation of an isoenzyme of human glutaminyl cyclase: retention in the Golgi complex suggests involvement in the protein maturation machinery. , 2008, Journal of molecular biology.